Literature DB >> 27515394

First next-generation sequencing full-genome characterization of a hepatitis C virus genotype 7 divergent subtype.

M Salmona1, A Caporossi2, P Simmonds3, M-A Thélu4, K Fusillier5, S Mercier-Delarue1, N De Castro6, J LeGoff1, M-L Chaix1, O François7, F Simon1, P Morand8, S Larrat8, S Maylin9.   

Abstract

We report the near-full-length genome sequence of a hepatitis C virus (HCV) isolate from a man originating from Democratic Republic of Congo, the genotype of which could not be determined by the routinely used sequencing technique. The near-complete genome sequence of this variant BAK1 was obtained by the association of two next-generation sequencing technologies. Evolutionary analysis indicates that this isolate, BAK1, could be the first reported strain belonging to a new HCV-7b subtype. This new subtype has been incorrectly identified as genotype 2 by the Versant HCV Genotype 2.0 assay (LiPA). The requirement of three independent isolates has been filled, and a new subtype can be assigned. More examples of HCV-7 are required to better understand its origin, its pathogenicity and its relationship with genotype 2.
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Democratic Republic of Congo; Genotype 7b; Hepatitis C virus; Next-generation sequencing; Polymorphism

Mesh:

Year:  2016        PMID: 27515394     DOI: 10.1016/j.cmi.2016.07.032

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  7 in total

1.  Efficient and unbiased metagenomic recovery of RNA virus genomes from human plasma samples.

Authors:  Carmen F Manso; David F Bibby; Jean L Mbisa
Journal:  Sci Rep       Date:  2017-06-23       Impact factor: 4.379

2.  Evaluation of the cobas® GT hepatitis C virus genotyping assay in G1-6 viruses including low viral loads and LiPA failures.

Authors:  Benjamin Némoz; Léa Roger; Vincent Leroy; Jean-Dominique Poveda; Patrice Morand; Sylvie Larrat
Journal:  PLoS One       Date:  2018-03-22       Impact factor: 3.240

3.  Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.

Authors:  Preethi Krishnan; Tami Pilot-Matias; Gretja Schnell; Rakesh Tripathi; Teresa I Ng; Thomas Reisch; Jill Beyer; Tatyana Dekhtyar; Michelle Irvin; Wangang Xie; Lois Larsen; Federico J Mensa; Christine Collins
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

Review 4.  Hepatitis C Virus Epitope Immunodominance and B Cell Repertoire Diversity.

Authors:  Nicholas A Brasher; Anurag Adhikari; Andrew R Lloyd; Nicodemus Tedla; Rowena A Bull
Journal:  Viruses       Date:  2021-05-25       Impact factor: 5.048

5.  Highly Diverse Hepatitis C Strains Detected in Sub-Saharan Africa Have Unknown Susceptibility to Direct-Acting Antiviral Treatments.

Authors:  Chris Davis; George S Mgomella; Ana da Silva Filipe; Eric H Frost; Genevieve Giroux; Joseph Hughes; Catherine Hogan; Pontiano Kaleebu; Gershim Asiki; John McLauchlan; Marc Niebel; Ponsiano Ocama; Cristina Pomila; Oliver G Pybus; Jacques Pépin; Peter Simmonds; Joshua B Singer; Vattipally B Sreenu; Clara Wekesa; Elizabeth H Young; Donald G Murphy; Manj Sandhu; Emma C Thomson
Journal:  Hepatology       Date:  2019-03-22       Impact factor: 17.425

6.  Positive Selection of ORF1ab, ORF3a, and ORF8 Genes Drives the Early Evolutionary Trends of SARS-CoV-2 During the 2020 COVID-19 Pandemic.

Authors:  Lauro Velazquez-Salinas; Selene Zarate; Samantha Eberl; Douglas P Gladue; Isabel Novella; Manuel V Borca
Journal:  Front Microbiol       Date:  2020-10-23       Impact factor: 5.640

7.  Characterization of a Novel Hepatitis C Subtype, 6xj, and Its Consequences for Direct-Acting Antiviral Treatment in Yunnan, China.

Authors:  Yuanyuan Jia; Wei Yue; Qinghua Gao; Rui Tao; Yaxiang Zhang; Xiaoyang Fu; Yang Liu; Li Liu; Yue Feng; Xueshan Xia
Journal:  Microbiol Spectr       Date:  2021-08-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.